Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Diagnosis & Disease Information
MRD-Guided Treatment Intensification Feasible in R/R Chronic Lymphocytic Leukemia
Researchers sought to determine whether uMRD could determine discontinuation of venetoclax or the addition of ibrutinib in patients with R/R CLL.
Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Meta-Analysis Clarifies Risk of Cutaneous AEs Associated With PI3K Inhibitors
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
Zanubrutinib Bests Bendamustine-Rituximab in Previously Untreated CLL/SLL
Zanubrutinib can improve progression-free survival, when compared with bendamustine-rituximab, in previously untreated CLL/SLL, a phase 3 trial suggests.
Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
TAp63 Expression Levels May Drive Disease Aggressiveness in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was a link between TAp63 and disease aggressiveness in patients with CLL.
Lisocabtagene Maraleucel Associated With Manageable Toxicities, Deep Responses in Relapsed/Refractory CLL or SLL
Researchers sought to determine whether liso-cel would have acceptable toxicity and effectiveness in patients with SLL or CLL.
Vaccine-Induced Responses to Omicron, Delta Impaired in Non-Hodgkin Lymphoma Patients
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
- Loading...
Loading...
Loading... 
Loading...